Belantamab mafodotin联合来那度胺地塞米松治疗不适合移植的新诊断骨髓瘤
BelaRd 1/2期研究评估belantamab mafodotin联合来那度胺地塞米松在不适合移植的新诊断多发性骨髓瘤中的疗效与安全性。Part 1确定推荐2期剂量为1.9 mg/kg每8周。在RP2D患者中总缓解率97.6%,18个月PFS率83.0%,眼毒性可管理。
要点
- BelaRd方案在不适合移植NDMM中ORR达97.6%,18个月PFS率83.0%。
- 推荐2期剂量为belamaf 1.9 mg/kg每8周一次。
- 血液科医生主导的VRA工具评估眼毒性可行,或可减少眼科评估需求。
核心结论
- BelaRd是不适合移植的新诊断多发性骨髓瘤的有效方案,值得开展3期研究。
- 眼不良事件对生活质量影响似乎有限。
研究设计与样本
- 1/2期BelaRd研究,Part 1纳入36例确定推荐2期剂量。
- Part 2随机30例,A组15例按眼科医生评估的眼不良事件指导给药,B组15例按血液科医生VRA工具及眼科医生评估的≥3级眼不良事件指导给药。
主要发现
- 推荐2期剂量为belamaf 1.9 mg/kg每8周一次,中位随访39.3个月。
- RP2D患者(n=42)总缓解率97.6%,中位PFS和OS未达到。
- 18个月PFS率和至进展时间率分别为83.0%和97.2%。
- 血液科医生与眼科医生评估的眼毒性相似,无眼科医生否决血液科医生给药决策的情况。
- 不足1%患者因眼不良事件停止驾驶/阅读,belamaf再输注中位时间13周。
关键数值与推荐
- 推荐belamaf 2期剂量为1.9 mg/kg每8周一次。
- RP2D患者总缓解率97.6%,18个月PFS率83.0%,至进展时间率97.2%。
临床怎么用
- BelaRd可作为不适合移植NDMM的治疗选择。
- 血液科医生主导的VRA工具可用于指导belamaf给药,可能减少眼科评估需求。
局限性
- 样本量较小(Part 1 n=36,Part 2 n=30)。
- 中位PFS和OS尚未达到。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The phase 1/2 BelaRd (belantamab mafodotin [belamaf], lenalidomide, and dexamethasone) study evaluated the efficacy and safety of belamaf combined with lenalidomide and dexamethasone in unfit and frail transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). Part 1 (n = 36) established a recommended belamaf phase 2 dose (RP2D) of 1.9 mg/kg every 8 weeks (median follow-up, 39.3 months). In part 2, 30 patients were randomized 1:1 in group A (n = 15), where belamaf dosing was guided by ophthalmologist-assessed ocular adverse events (OAEs), whereas in group B (n = 15), belamaf dosing was based on hematologist-led vision-related anamnestic (VRA) tool and ophthalmologist-assessed grade ≥3 OAEs. Among the RP2D patients (n = 42), overall response rate was 97.6%, median progression-free survival (PFS)/overall survival have not been reached yet, and the 18-month PFS and time to progression rates were 83.0% and 97.2%, respectively. Ocular toxicities were similar between assessments by hematologists and ophthalmologists, and no ophthalmologist withholding of a hematologist-led dosing occurred. Less than 1% of patients stopped driving/reading because of OAEs. Median time to belamaf reinfusion was 13 weeks. Overall, BelaRd is an effective regimen for transplant-ineligible patients with NDMM and warrants a phase 3 study in this setting. OAEs' impact on quality of life appears limited, and implementation of the hematologist-led VRA tool may eventually reduce the necessity for ophthalmologist assessments. This trial was registered at www.clinicaltrials.gov as #NCT04808037.
引用
- Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, et al. Belantamab mafodotin, lenalidomide, and dexamethasone for intermediate-fit and frail patients with newly diagnosed myeloma. Blood. 2026. PMID: 41346230. doi:10.1182/blood.2025031629
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。